Literature DB >> 21537384

LRP-1 variation is not associated with risk of Alzheimer's disease.

Katy A Chalmers, Rachel Barker, Peter A Passmore, Francesco Panza, Davide Seripa, Vincenzo Solfrizzi, Seth Love, Jonathan A Prince, Patrick G Kehoe.   

Abstract

Alzheimer's disease (AD) is characterised by the extensive deposition of amyloid beta (Aβ) within the parenchyma and vasculature of the brain. It is hypothesised that a dysfunction in Aβ degradation and/or its removal from the brain may result in accumulation as plaques. Low density lipoprotein receptor-related protein-1 (LRP-1) is a multifunctional receptor shown to be involved in cholesterol metabolism but also the removal of Aβ from the brain. Its ability to transport Aβ from the brain to the periphery has made it an attractive candidate for involvement in Alzheimer's disease (AD). We have assessed the frequencies of 9 tag- SNPs and the commonly studied synonymous SNP within exon 3 (rs1799986) in a multi-centre AD/control cohort and performed haplotype analysis. We found no evidence from a combined total of 412 controls and 1057 AD patients to support the involvement of LRP-1 variation, including the most commonly studied variant in rs1799986 in conferring genetic susceptibility to increased risk of AD.

Entities:  

Keywords:  Alzheimer's disease; LRP-1; association analysis

Year:  2010        PMID: 21537384      PMCID: PMC3076756     

Source DB:  PubMed          Journal:  Int J Mol Epidemiol Genet        ISSN: 1948-1756


  37 in total

Review 1.  Abeta-degrading enzymes in Alzheimer's disease.

Authors:  James Scott Miners; Shabnam Baig; Jennifer Palmer; Laura E Palmer; Patrick G Kehoe; Seth Love
Journal:  Brain Pathol       Date:  2008-04       Impact factor: 6.508

2.  Glycoprotein 330/megalin: probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer disease amyloid beta at the blood-brain and blood-cerebrospinal fluid barriers.

Authors:  B V Zlokovic; C L Martel; E Matsubara; J G McComb; G Zheng; R T McCluskey; B Frangione; J Ghiso
Journal:  Proc Natl Acad Sci U S A       Date:  1996-04-30       Impact factor: 11.205

Review 3.  The role of proteolysis in Alzheimer's disease.

Authors:  N M Hooper; A J Trew; E T Parkin; A J Turner
Journal:  Adv Exp Med Biol       Date:  2000       Impact factor: 2.622

4.  Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier.

Authors:  M Shibata; S Yamada; S R Kumar; M Calero; J Bading; B Frangione; D M Holtzman; C A Miller; D K Strickland; J Ghiso; B V Zlokovic
Journal:  J Clin Invest       Date:  2000-12       Impact factor: 14.808

5.  Complete genomic screen in late-onset familial Alzheimer disease. Evidence for a new locus on chromosome 12.

Authors:  M A Pericak-Vance; M P Bass; L H Yamaoka; P C Gaskell; W K Scott; H A Terwedow; M M Menold; P M Conneally; G W Small; J M Vance; A M Saunders; A D Roses; J L Haines
Journal:  JAMA       Date:  1997-10-15       Impact factor: 56.272

6.  LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms.

Authors:  Rashid Deane; Zhenhua Wu; Abhay Sagare; Judianne Davis; Shi Du Yan; Katie Hamm; Feng Xu; Margaret Parisi; Barbra LaRue; Hong Wei Hu; Patricia Spijkers; Huang Guo; Xiaomei Song; Peter J Lenting; William E Van Nostrand; Berislav V Zlokovic
Journal:  Neuron       Date:  2004-08-05       Impact factor: 17.173

7.  The cerebrospinal-fluid soluble form of Alzheimer's amyloid beta is complexed to SP-40,40 (apolipoprotein J), an inhibitor of the complement membrane-attack complex.

Authors:  J Ghiso; E Matsubara; A Koudinov; N H Choi-Miura; M Tomita; T Wisniewski; B Frangione
Journal:  Biochem J       Date:  1993-07-01       Impact factor: 3.857

8.  Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease.

Authors:  Denise Harold; Richard Abraham; Paul Hollingworth; Rebecca Sims; Amy Gerrish; Marian L Hamshere; Jaspreet Singh Pahwa; Valentina Moskvina; Kimberley Dowzell; Amy Williams; Nicola Jones; Charlene Thomas; Alexandra Stretton; Angharad R Morgan; Simon Lovestone; John Powell; Petroula Proitsi; Michelle K Lupton; Carol Brayne; David C Rubinsztein; Michael Gill; Brian Lawlor; Aoibhinn Lynch; Kevin Morgan; Kristelle S Brown; Peter A Passmore; David Craig; Bernadette McGuinness; Stephen Todd; Clive Holmes; David Mann; A David Smith; Seth Love; Patrick G Kehoe; John Hardy; Simon Mead; Nick Fox; Martin Rossor; John Collinge; Wolfgang Maier; Frank Jessen; Britta Schürmann; Reinhard Heun; Hendrik van den Bussche; Isabella Heuser; Johannes Kornhuber; Jens Wiltfang; Martin Dichgans; Lutz Frölich; Harald Hampel; Michael Hüll; Dan Rujescu; Alison M Goate; John S K Kauwe; Carlos Cruchaga; Petra Nowotny; John C Morris; Kevin Mayo; Kristel Sleegers; Karolien Bettens; Sebastiaan Engelborghs; Peter P De Deyn; Christine Van Broeckhoven; Gill Livingston; Nicholas J Bass; Hugh Gurling; Andrew McQuillin; Rhian Gwilliam; Panagiotis Deloukas; Ammar Al-Chalabi; Christopher E Shaw; Magda Tsolaki; Andrew B Singleton; Rita Guerreiro; Thomas W Mühleisen; Markus M Nöthen; Susanne Moebus; Karl-Heinz Jöckel; Norman Klopp; H-Erich Wichmann; Minerva M Carrasquillo; V Shane Pankratz; Steven G Younkin; Peter A Holmans; Michael O'Donovan; Michael J Owen; Julie Williams
Journal:  Nat Genet       Date:  2009-09-06       Impact factor: 38.330

9.  LRP1 modulates APP trafficking along early compartments of the secretory pathway.

Authors:  Elaine Waldron; Catherine Heilig; Andrea Schweitzer; Nirupa Nadella; Sebastian Jaeger; Anne M Martin; Sascha Weggen; Klaudia Brix; Claus U Pietrzik
Journal:  Neurobiol Dis       Date:  2008-05-03       Impact factor: 5.996

Review 10.  Insights into the pathogenesis and pathogenicity of cerebral amyloid angiopathy.

Authors:  Seth Love; Scott Miners; Jen Palmer; Katy Chalmers; Patrick Kehoe
Journal:  Front Biosci (Landmark Ed)       Date:  2009-01-01
View more
  7 in total

Review 1.  Dyslipidemia and dementia: current epidemiology, genetic evidence, and mechanisms behind the associations.

Authors:  Christiane Reitz
Journal:  J Alzheimers Dis       Date:  2012       Impact factor: 4.472

Review 2.  Low-density lipoprotein receptor-related protein 1: a physiological Aβ homeostatic mechanism with multiple therapeutic opportunities.

Authors:  Abhay P Sagare; Rashid Deane; Berislav V Zlokovic
Journal:  Pharmacol Ther       Date:  2012-07-20       Impact factor: 12.310

Review 3.  Neurovascular Alterations in Alzheimer's Disease: Transporter Expression Profiles and CNS Drug Access.

Authors:  Mitchell P McInerney; Jennifer L Short; Joseph A Nicolazzo
Journal:  AAPS J       Date:  2017-05-01       Impact factor: 4.009

Review 4.  Low-density lipoprotein receptor-related protein-1: a serial clearance homeostatic mechanism controlling Alzheimer's amyloid β-peptide elimination from the brain.

Authors:  Berislav V Zlokovic; Rashid Deane; Abhay P Sagare; Robert D Bell; Ethan A Winkler
Journal:  J Neurochem       Date:  2010-10-05       Impact factor: 5.372

5.  Genetic variation in MME in relation to neprilysin protein and enzyme activity, Aβ levels, and Alzheimer's disease risk.

Authors:  Scott Miners; Zoë van Helmond; Rachel Barker; Peter A Passmore; Janet A Johnston; Stephen Todd; Bernadette M McGuinness; Francesco Panza; Davide Seripa; Vincenzo Solfrizzi; Seth Love; Jonathan A Prince; Patrick G Kehoe
Journal:  Int J Mol Epidemiol Genet       Date:  2012-02-05

6.  Predicting survival using clinical risk scores and non-HLA immunogenetics.

Authors:  Y Balavarca; K Pearce; J Norden; M Collin; G Jackson; E Holler; R Dressel; H-J Kolb; H Greinix; G Socie; A Toubert; V Rocha; E Gluckman; I Hromadnikova; P Sedlacek; D Wolff; U Holtick; A Dickinson; H Bickeböller
Journal:  Bone Marrow Transplant       Date:  2015-07-27       Impact factor: 5.483

7.  Deterioration of cognitive function after transient cerebral ischemia with amyloid-β infusion-possible amelioration of cognitive function by AT2 receptor activation.

Authors:  Li-Juan Min; Jun Iwanami; Masachika Shudou; Hui-Yu Bai; Bao-Shuai Shan; Akinori Higaki; Masaki Mogi; Masatsugu Horiuchi
Journal:  J Neuroinflammation       Date:  2020-04-07       Impact factor: 8.322

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.